依达拉奉联合瑞舒伐他汀治疗心源性脑梗死的疗效及对血清CXCL12、UCH-L1、HC-gp39水平的影响

目的 探究依达拉奉联合瑞舒伐他汀治疗心源性脑梗死的疗效及对血清趋化因子12（CXCL12）、泛素C末端水解酶L1（UCH-L1）、人类软骨糖蛋白-39（HC-gp39）水平的影响。方法 选取2020年3月—2022年4月达州市中心医院收治的90例心源性脑梗死患者作为研究对象,随机分为对照组和观察组,各45例。对照组给予瑞舒伐他汀治疗,观察组给予依达拉奉联合瑞舒伐他汀治疗。比较两组疗效、CXCL12、UCH-L1、HC-gp39、血液流变学指标、血脂水平及美国国立卫生研究院脑卒中量表（NIHSS）评分。结果 观察组总有效率高于对照组（P <0.05）。观察组治疗前后血清CXCL12、UCH-L1、HC-gp39水平的差值高于对照组（P <0.05）。观察组治疗前后全血低切黏度、全血高切黏度及纤维蛋白原水平的差值高于对照组（P <0.05）。观察组治疗前后TC、TG、LDL-C水平的差值高于对照组（P <0.05）。观察组治疗前后NIHSS评分的差值高于对照组（P <0.05）。结论 依达拉奉联合瑞舒伐他汀治疗心源性心肌梗死可有效提高患者临床疗效,改善血液流变学指标、血脂、神经功能及炎症反应。     

生后人肺神经内分泌细胞的形态学观察—免疫组织化学及电镜研究

用银染色法、免疫组织化学及透射电镜技术，对３６例人肺的神经内分泌细胞进行了形态学和免疫组织化学观察。提示ＮＥ细胞发生了废用性退化，其原因可能与出生前后人肺功能改变有关。     

Reaction of chitosan with genipin and its fluorogenic attributes for potential microcapsule membrane characterization

This study investigates the fluorogenic characteristics of the chitosan-genipin reaction for applications in microencapsulation research. Results showed that the chitosan-genipin reaction generated a colored and fluorescent product, with optimal excitation and emission wavelengths at 369 and 470 nm, respectively. Furthermore, it was found that reaction conditions affected the fluorescence intensity of the product. Mixture at the ratio of 4:1 (chitosan: genipin by weight) fluoresced the most. It also fluoresced stronger if the reaction occurred at higher temperature, with the intensity of 10.4 x 10(5) CPS at 37 degrees C, 5.9 x 10(5) CPS at 20 degrees C, and 2.5 x 10(5) CPS at 4 degrees C. As well, the fluorescence of the mixture developed gradually over time, attaining the emission maxima of 2.9 x 10(5), 7.6 x 10(5), and 10.0 x 10(5) CPS in 1, 6, and 18 h, respectively. Chitosan-coated alginate microcapsules were prepared without prior labeling, to which subsequent genipin treatment was applied in order to examine the potential of using genipin in microcapsule characterization. Chitosan bound to the alginate beads interacted with genipin, from which the resultant fluorescent signals allowed for clear visualization of the chitosan coating under confocal laser scanning microscopy. The relative fluorescence intensity across the chitosan membrane was found to be considerably higher than the controls (175 vs. 50). The membrane thickness measured was 29.2 +/- 7.3 microm. These findings demonstrate a convenient and effective way of characterizing chitosan-based microcapsules using genipin as a fluorogenic marker, a technique that will be useful in microcapsule research and other biomedical applications.     

Holter系统的技术要求及神经网络方法

为了长时间、准确的记录分分析体表ＥＣＧ，从各个方面满足基础研究、临床、康复以及特殊生理需要，对Ｈｏｌｔｅｒ系统提出了愈来愈高的要求。作者从技术实现的角度讨论了Ｈｏｌｔｅｒ的主要技术要求，包括记录部分和分析部分；还介绍了几种用神经网络模型满足Ｈｏｌｔｅｒ系统技术要求的原理，包括用多层感知器实现数据压缩及分类，用高阶神经网络实现ＥＣＧ的分类，以及用ＡＲＴ模型识别ＥＣＧ中的Ｐ波与Ｔ波。     

带臂外侧上皮神经及其营养血管筋膜皮瓣的应用解剖

目的:为带臂外侧上皮神经及其营养血管筋膜皮瓣提供解剖学基础.方法:32例经灌注红色乳胶的成人上肢标本,对臂外侧上皮神经及其营养血管等进行了较详细的应用解剖学研究.结果:臂外侧上皮神经在均由腑神经发出,起点横径为1.5±0.4mm,在三角肌深方斜向外下3.6±1.1cm从该肌后缘中1/3浅出肌间隔,分为上支和下支,分布于三角肌后部、外侧部和臂外侧上部.该神经的营养血管起源于旋肱后动脉,起点外径为0.9±0.4mm;其行程、分支和分布均同在神经,供血范因为14.8×9.8cm~2,并与周围的皮动脉存在丰富吻合.结论:带臂外侧上皮神经及其营养血管筋膜皮 瓣可视受区需要设计成游离瓣或旋转瓣,用于修复邻近部位、手或颌面部缺损.     

大白鼠下丘脑促肾上腺皮质激素(ACTH)样免疫反应神经元的分布及功能意义

本文应用免疫细胞化学技术观察大白鼠下丘脑促肾上腺皮质激素样神经元胞体,纤维及串珠样膨体的分布。胞体位于弓状核、下丘脑前核的腹侧、视上背侧连合、室周层的腹侧区及乳头体核腹侧。纤维及串珠样膨体广泛地分布于下丘脑,串珠样膨体在室旁核和室周层密集。串珠样膨体贴室管膜分布,伸至室管膜下神经毯,有的穿行室管膜上皮细胞之间并多与室管膜上皮细胞接触或穿过室管膜上皮细胞之间至第三脑室腔。在第三脑室侧壁的室管膜上皮细胞之间偶见促肾上腺皮质激素反应细胞。室旁核区促肾上腺皮质激素免疫反应串珠样膨体可能作用于催产素和后叶加压素神经元,控制催产素和后叶加压素的分泌和释放。室周层的串珠样膨体直接与脑脊液接触可认为是促肾上腺皮质激素神经元释放分泌产物的另一途径。     

不同年龄组儿童甲状腺测量值及其变化的研究

调查了90具童尸用状腺的基本形态,可分四型。其中以甲状腺由两侧叶及峡部组成者为最多,占50.22%。测量了甲状腺各部的长、宽、厚。分年龄组进行了数据的统计学处理,并计算出儿童与成人甲状腺各部相应值的百分比。结果显示:小儿甲状腺侧叶的长度和宽度在幼儿期(1—3岁)就已发育近成人的一半。随着年龄的增长,甲状腺各部的均值逐渐增加。除各部的宽度以及锥体叶的长度外,各相邻两组间同项均数的比较,经双侧T检验发现差异具有高度显著性(P<0.01)。     

西拉普利对低氧大鼠肺动脉和心肌细胞增殖的抑制作用

目的：探索cilazapril 对低氧大鼠肺血管和心肌细胞增殖的抑制机理。 方法： 采用生化、放射免疫、免疫组织化学、细胞凋亡标记和血流动力学技术研究低氧肺血管及心肌细胞增殖和结构重建。 结果： （1）低氧大鼠mPAP显著增高，伴有肺动脉血管管腔狭窄、管壁增厚，心肌肥大，R/L+S增高。（2）B组、C组大鼠肺动脉和右心肌细胞增殖指数（PI）均分别明显高于A组，而C组明显低于B组。ET-1免疫组化染色阳性细胞主要分布在肺动脉血管壁和心肌细胞上，染色程度由强到弱依次为B组>C组>A组。（3）B组大鼠ET-1水平和ACE活性明显高于A组，而C组显著低于B组。（4）直线相关分析显示ET-1、ACE分别与R/(L+S)、mPAP、肺动脉PI、心肌PI呈正相关；多元回归分析显示ET-1和ACE可能是影响PI的主要因素。 结论： 低氧大鼠存在细胞过度增殖状态，继发肺血管、右心结构重建是低氧性肺动脉高压发病机理之一。Cilazapril通过抑制ACE和ET-1的促增殖作用，阻止肺血管及心肌重建，对低氧性肺动脉高压的防治有一定作用。     

Wu T_(11)(CD2)-小鼠抗人绵羊红细胞受体杂交瘤细胞系的建立

本文报道用T细胞系JMN1免疫BALB/c小鼠,然后取免疫脾细胞与小鼠骨髓瘤细胞系X 63Ag8.653融合。用扁桃腺冰冻切片免疫酶染色法,筛选出一株稳定分泌IgG1亚类的抗绵羊红细胞受体(ER)单扰(McAb)的杂交瘤—WuT11。通过E玫瑰花结形成抑制试验,膜抗原抽提物对WuT11的间接免疫荧光阻断试验,对外周血单个核细胞(PBMC)及其E~ 、E~-层细胞,T、B和非T非B细胞系的反应特征以及FACS的反应曲线等,证明WuT11与OKT11和anti-CCT3相类似,竞争抑制试验证明WuT11与anti-CCT3识别同一表位。用WuT11进行亲和层析,提取的相应抗原经SDS-PAGE,测得分子量为50KDa的糖蛋白,证明WuT11属CD_2,为识别人ER的单抗。     

Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections

Background

The missing asymptomatic COVID-19 infections have been overlooked because of the imperfect sensitivity of the nucleic acid testing (NAT). Globally understanding the humoral immunity in asymptomatic carriers will provide scientific knowledge for developing serological tests, improving early identification, and implementing more rational control strategies against the pandemic.

Measure

Utilizing both NAT and commercial kits for serum IgM and IgG antibodies, we extensively screened 11 766 epidemiologically suspected individuals on enrollment and 63 asymptomatic individuals were detected and recruited. Sixty-three healthy individuals and 51 mild patients without any preexisting conditions were set as controls. Serum IgM and IgG profiles were further probed using a SARS-CoV-2 proteome microarray, and neutralizing antibody was detected by a pseudotyped virus neutralization assay system. The dynamics of antibodies were analyzed with exposure time or symptoms onset.

Results

A combination test of NAT and serological testing for IgM antibody discovered 55.5% of the total of 63 asymptomatic infections, which significantly raises the detection sensitivity when compared with the NAT alone (19%). Serum proteome microarray analysis demonstrated that asymptomatics mainly produced IgM and IgG antibodies against S1 and N proteins out of 20 proteins of SARS-CoV-2. Different from strong and persistent N-specific antibodies, S1-specific IgM responses, which evolved in asymptomatic individuals as early as the seventh day after exposure, peaked on days from 17 days to 25 days, and then disappeared in two months, might be used as an early diagnostic biomarker. 11.8% (6/51) mild patients and 38.1% (24/63) asymptomatic individuals did not produce neutralizing antibody. In particular, neutralizing antibody in asymptomatics gradually vanished in two months.

Conclusion

Our findings might have important implications for the definition of asymptomatic COVID-19 infections, diagnosis, serological survey, public health, and immunization strategies.